Last --
Change Today 0.00 / 0.00%
Volume 0.0
AEMAY On Other Exchanges
All times are local (Market data is delayed by at least 15 minutes).

alchemia ltd-sponsored adr (AEMAY) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

alchemia ltd-sponsored adr (AEMAY) Related Businessweek News

No Related Businessweek News Found

alchemia ltd-sponsored adr (AEMAY) Details

Alchemia Limited, a biotechnology company, develops human therapeutic products based on its proprietary drug discovery, drug targeting, and synthesis technologies in Australia and the United States. Its technologies include HyACT, a platform technology that uses the non-toxic and naturally occurring carbohydrate, hyaluronic acid as a drug delivery vehicle for a range of approved anti-cancer therapeutics; and Versatile Assembly on Stable Templates technology, a small molecule drug discovery technology. The company also provides generic fondaparinux, an anticoagulant drug for the prevention and treatment of deep vein thrombosis and pulmonary embolism. In addition, it develops HA-Irinotecan that is in Phase III clinical trials for the treatment of metastatic colorectal cancer, as well as in the phase II investigator-sponsored trials that focuses on small cell lung cancer. The company has collaboration agreements with AstraZeneca AB to discover and develop novel small molecules against multiple targets; Merck Serono to develop HA-Irinotecan in combination with therapeutic antibody, Erbitux (cetuximab), for patients with metastatic colorectal cancer; and IMBcom Asset Management Company for conducting research based upon certain voltage gated ion channel biological targets and library compounds, as well as with University of Queensland for ion channel drug discovery. Alchemia Limited also has research agreement with Monash University; and Cancer Research Technology Limited. The company was founded in 1995 and is headquartered in Brisbane, Australia.

29 Employees
Last Reported Date: 08/29/14
Founded in 1995

alchemia ltd-sponsored adr (AEMAY) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$185.6K
Chief Scientific Officer and Vice President o...
Total Annual Compensation: A$235.7K
Vice President of Business Development
Total Annual Compensation: A$197.8K
Group Financial Controller
Total Annual Compensation: A$193.4K
Vice President of Drug Discovery
Total Annual Compensation: A$224.3K
Compensation as of Fiscal Year 2014.

alchemia ltd-sponsored adr (AEMAY) Key Developments

Alchemia Announces Database Lock of HA-Irinotecan Pivotal Phase III Trial in Metastatic Colorectal Cancer

Alchemia Limited announced the database lock for the primary efficacy analysis of its pivotal Phase III trial of HA-Irinotecan in metastatic colorectal cancer (mCRC). The company also confirms that the trial achieved its primary endpoint analysis threshold of a minimum of 350 progression free survival (PFS) events. The statistical analysis of the clinical study was designed to commence when 350 progression-free survival events had been confirmed by the trial's independent Imaging Review Committee. The database lock means no further changes to the trial data will occur and that data analysis will commence. The data collection and reconciliation, as well as the query resolution procedures and quality control have been completed, enabling the locking of the database. The validated dataset has been finalised and submitted to Alchemia's project statisticians for analysis pursuant to the trial's protocols. Results for the trial, which has successfully completed four safety reviews by the Data Safety Monitoring Board (DSMB), are expected to be released by the end of October 2014. The Phase III trial enrolled 415 patients across 76 clinical centres worldwide. It was a randomized, double-blinded, active controlled study of Alchemia's proprietary HyACT technology formulated with the well-known chemotherapeutic drug, irinotecan. HA-Irinotecan or irinotecan were administered as part of the conventional FOLFIRI chemotherapy regimen (combination of folinic acid, fluorouracil and irinotecan) in patients with mCRC who were candidates for second or third line chemotherapy. The primary objective of this trial was to demonstrate superiority in progression free survival (PFS) of Alchemia's HA-Irinotecan over irinotecan.

Alchemia Limited Announces Consolidated Preliminary Earnings Results for the Full Year Ended June 30, 2014

Alchemia Limited announced consolidated preliminary earnings results for the full year ended June 30, 2014. For the year, the company reported total revenues of AUD 15,811,000 compared with AUD 24,297,000 for the same period a year ago. Loss from continuing operations before income tax was AUD 7,186,000 compared with AUD 5,043,000 for the same period a year ago. Net loss from continuing operations was AUD 6,924,000 or 2.1 cents per basic and diluted share compared with AUD 4,770,000 or 1.6 cents per basic and diluted share for the same period a year ago. Net cash flows used in operating activities was AUD 1,621,000 compared with AUD 13,524,000 for the same period a year ago. Purchase of property, plant and equipment was AUD 249,000 compared with AUD 94,000 for the same period a year ago.

Alchemia Limited Appoints Jenni Pilcher as Chief Financial Officer, Effective on September 1, 2014

Alchemia Limited announced the appointment of Ms. Jenni Pilcher as its Chief Financial Officer (CFO). Ms. Pilcher brings extensive financial leadership experience to Alchemia. She is currently the CFO of Mesoblast, where she has been part of the executive team for the past seven years, and she also serves as Company Secretary. Jenni's appointment is effective on September 1, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEMAY:US $0.00 USD 0.00

AEMAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEMAY.
View Industry Companies

Industry Analysis


Industry Average

Valuation AEMAY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.3x
Price/Book 7.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALCHEMIA LTD-SPONSORED ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at